Author index

A

Abdulkadir, J. 222
Adamson, U. 152
Agardh, C.-D. 319
Ah-See, A. K. 311
Akashi, M. 597
Akazawa, M. 597
Akazawa, S. 597
Åkerblom, H. K. 357, 509
Alamowitch, C. 671
Alberti, K. G. M. M. 417, 497
Allen, J. A. 350
Aperia, A. 470
Ariav, Y. 482
Arnqvist, H. J. 334
Asakawa, H. 105
Asplund, K. 244
Assa, S. 557
Atkinson, A. B. 681

B

Baba, S. 266
Baba, T. 121
Bailbe, D. 654
Bailey, C. J. 462
Baird, J. D. 257
Baker, L. 593
Bar-On, H. 197
Barbanti, M. 163, 205
Barnett, A. H. 387
Battezzati, A. 549
Beacham, J. 115
Beales, P. E. 635
Beaufort, C. de 465
Beck-Nielsen, H. 603, 625
Beer, S. F. 497
Bekele, A. 222
Bell, G. I. 628
Bell, P. M. 681
Ben-Sasson, R. 197
Bendayan, M. 197, 661
Benn, J. J. 158
Bennet, W. M. 43
Bennett, P. H. 285, 438
Berger, M. 121, 384, 696
Bergström, B. 148
Bergstrom, R. W. 489
Beylot, M. 449
Bianchi, R. 131
Binder, C. 36
Bloom, S. R. 115, 306
Boitard, C. 731
Bolli, G. B. 52
Bomford, J. 278, 371
Bone, A. J. 257
Bonifacio, E. 60, 731
Borch-Johnsen, K. 407, 619
Bornfeldt, K. E. 334
Bosi, E. 719
Bottazzo, G. F. 731
Bougneres, P. 411
Bouillenne, C. 719
Boulton, A. J. M. 311, 431
Bradley, J. 611
Bradwell, A. R. 387
Brahm, J. 619
Bramnert, M. 148
Bréant, B. 586
Bretherton-Watt, D. 115
Bretzel, R. G. 112
Brunetti, P. 52
Buonocore, S. 272
Buschard, K. 31
Butler-Simon, N. 444

C

Caldwell, G. 262
Cameron, S. O. 290
Capron, F. 457
Caputo, S. 726
Caspary, W. F. 65
Castoldi, R. 549
Cerasi, E. 482
Ceriello, A. 163, 205
Cha, C. Y. 569
Charbonnel, B. 9
Chase, H. P. 444
Chatterton, B. E. 675
Chicheportiche, D. 457
Christensen, P. 15
Clark, A. 285
Clark, P. 631
Clark, P. M. S. 532
Clemons, G. K. 378
Clerget-Darpoux, F. 425
Cohen, R. 449
Collignon, A. 465
Collins, P. 93
Compton, A. M. 311
Comstock, J. 431
Connacher, A. A. 43
Cooper, T. M. 532
Corcos, A. P. 482
Czernichow, P. 174, 465

D

Damsbo, P. 625
Dandona, P. 417
Darquy, S. 457
Das, A. 515
Dausset, J. 425
Davie, S. 208
Davies, E. G. 262
Day, C. 462
De Bernardi, P. 187
De Feo, P. 52
De Hertogh, R. 187
De Meyer, R. 187
Deckert, T. 407, 619
DeFronzo, R. 168
Del Prato, S. 228, 688
Dent, J. 675
Deschamps, I. 425
Desjardins, M. 661
Desplanque, N. 671
Di Carlo, V. 549
Di Leo, M. A. S. 726
Dinarello, C. A. 15
D'Onofrio, F. 272, 511
Dosso, A. 137
Doutreix, J. 465
Dowd, J. E. 3
Dronfield, D. M. 325
Duner, E. 688

E

Egler, J. 593
Elion, J. 174
Engerman, R. L. 522
Engström, K. G. 127
Ennis, C. N. 681
Enzi, G. 228
Eriksson, K.-F. 526
Eriksson, S. 244
Ewing, D. J. 180

F

Fabris, M. 131
Facchini, F. 549
Falsini, B. 726
Fanelli, C. 52
Farquharson, M. A. 290
Federlin K. 112
Fehsel, K. 573
Feldt-Rasmussen, B. 407
Ferrari, G. 549
Ferrua, B. 411
Feve, B. 9
Fiori, M. G. 131
Flatt, P. R. 462
Flesch, B. K. 112
Fletcher, J. 387
Flyvbjerg, A. 334
Forrest, R. D. 208
Foulis, A. K. 290
François-Gérard, C. 719
Frank, R. N. 515
Fraser, R. J. 675
Freychet, P. 411
Freyschuss, U. 470
Frighi, V. 278, 371
Froment, V. 465
Fujimoto, W. Y. 489
Fuller, J. H. 477, 538, 542
Funder, J. 619
Furuta, H. 118

G

Gale, E. A. M. 635
Gardais, E. 425
Garg, S. 444
Garrido, M. C. 278, 371
Garrino, M. G. 145
Garros, B. 465
Gebre, P. 222
Gebriel, Z. W. 222
Gentile, S. 272
Ghatei, M. A. 115, 306
Ghirlanda, G. 726
Gilbey, S. G. 115
Gilcrease, M. Z. 329
Gilmore, J. E. 350
Giroix, M.-H. 654
Giugliano, D. 163, 205
Glaser, B. 482
Gleichmann, H. 731
Goldman, A. 593
Gould, B. J. 208
Grankvist, K. 127
Greco, A. V. 726
Greenbaum, C. 638
Grémeaux, T. 24
Gros, F. 661
Gubler, M. C. 661
Guillaume, Gentil, C. 137
Guilluy, R. 449

H

Hägg, E. 244
Halban, P. A. 77, 457
Hales, C. N. 532, 631
Hanafusa, T. 105, 503
Handberg, A. 625
Hanley, S. P. 311
Hanson, U. 100
Harding, P. E. 675
Hardisty, C. A. 177
Hari, J. 266
Harling, H. 403
Harrison, L. C. 641
Hartling, S. G. 36
Hashimoto, M. 597
Hatamori, N. 266
Hayakawa, M. 266
Hayashi, T. 192
Hayes, J. R. 350
Head, J. 477, 538, 542
Heaton, D. A. 497
Heding, L. 384
Heinemann, L. 384
Heller, S. R. 216
Hellerström, C. 1, 447
Hendra, T. J. 532
Henquin, J. C. 145
Herrera, J. 422
Heylen, L. 649
Hirayama, J. 118
Hockaday, T. D. R. 371, 417
Holst, J. J. 403
Hommel, E. 619
Hoops, S. L. 444
Hoover, R. L. 329
Horowitz, M. 675
Hors, J. 425
Hother-Nielsen, O. 603
Hougaard, P. 31
Hudson, B. G. 704
Huff, J. K. 704

Author index

A

Abdulkadir, J. 222
Adamson, U. 152
Agardh, C.-D. 319
Ah-See, A. K. 311
Akashi, M. 597
Akazawa, M. 597
Akazawa, S. 597
Åkerblom, H. K. 357, 509
Alamowitch, C. 671
Alberti, K. G. M. M. 417, 497
Allen, J. A. 350
Aperia, A. 470
Ariav, Y. 482
Arnqvist, H. J. 334
Asakawa, H. 105
Asplund, K. 244
Assa, S. 557
Atkinson, A. B. 681

B

Baba, S. 266
Baba, T. 121
Bailbe, D. 654
Bailey, C. J. 462
Baird, J. D. 257
Baker, L. 593
Bar-On, H. 197
Barbanti, M. 163, 205
Barnett, A. H. 387
Battezzati, A. 549
Beacham, J. 115
Beales, P. E. 635
Beaufort, C. de 465
Beck-Nielsen, H. 603, 625
Beer, S. F. 497
Bekele, A. 222
Bell, G. I. 628
Bell, P. M. 681
Ben-Sasson, R. 197
Bendayan, M. 197, 661
Benn, J. J. 158
Bennet, W. M. 43
Bennett, P. H. 285, 438
Berger, M. 121, 384, 696
Bergström, B. 148
Bergstrom, R. W. 489
Beylot, M. 449
Bianchi, R. 131
Binder, C. 36
Bloom, S. R. 115, 306
Boitard, C. 731
Bolli, G. B. 52
Bomford, J. 278, 371
Bone, A. J. 257
Bonifacio, E. 60, 731
Borch-Johnsen, K. 407, 619
Bornfeldt, K. E. 334
Bosi, E. 719
Bottazzo, G. F. 731
Bougneres, P. 411
Bouillenne, C. 719
Boulton, A. J. M. 311, 431
Bradley, J. 611
Bradwell, A. R. 387
Brahm, J. 619
Bramnert, M. 148
Bréant, B. 586
Bretherton-Watt, D. 115
Bretzel, R. G. 112
Brunetti, P. 52
Buonocore, S. 272
Buschard, K. 31
Butler-Simon, N. 444

C

Caldwell, G. 262
Cameron, S. O. 290
Capron, F. 457
Caputo, S. 726
Caspary, W. F. 65
Castoldi, R. 549
Cerasi, E. 482
Ceriello, A. 163, 205
Cha, C. Y. 569
Charbonnel, B. 9
Chase, H. P. 444
Chatterton, B. E. 675
Chicheportiche, D. 457
Christensen, P. 15
Clark, A. 285
Clark, P. 631
Clark, P. M. S. 532
Clemons, G. K. 378
Clerget-Darpoux, F. 425
Cohen, R. 449
Collignon, A. 465
Collins, P. 93
Compton, A. M. 311
Comstock, J. 431
Connacher, A. A. 43
Cooper, T. M. 532
Corcos, A. P. 482
Czernichow, P. 174, 465

D

Damsbo, P. 625
Dandona, P. 417
Darquy, S. 457
Das, A. 515
Dausset, J. 425
Davie, S. 208
Davies, E. G. 262
Day, C. 462
De Bernardi, P. 187
De Feo, P. 52
De Hertogh, R. 187
De Meyer, R. 187
Deckert, T. 407, 619
DeFronzo, R. 168
Del Prato, S. 228, 688
Dent, J. 675
Deschamps, I. 425
Desjardins, M. 661
Desplanque, N. 671
Di Carlo, V. 549
Di Leo, M. A. S. 726
Dinarello, C. A. 15
D'Onofrio, F. 272, 511
Dosso, A. 137
Doutreix, J. 465
Dowd, J. E. 3
Dronfield, D. M. 325
Duner, E. 688

E

Egler, J. 593
Elion, J. 174
Engerman, R. L. 522
Engström, K. G. 127
Ennis, C. N. 681
Enzi, G. 228
Eriksson, K.-F. 526
Eriksson, S. 244
Ewing, D. J. 180

F

Fabris, M. 131
Facchini, F. 549
Falsini, B. 726
Fanelli, C. 52
Farquharson, M. A. 290
Federlin K. 112
Fehsel, K. 573
Feldt-Rasmussen, B. 407
Ferrari, G. 549
Ferrua, B. 411
Feve, B. 9
Fiori, M. G. 131
Flatt, P. R. 462
Flesch, B. K. 112
Fletcher, J. 387
Flyvbjerg, A. 334
Forrest, R. D. 208
Foulis, A. K. 290
François-Gérard, C. 719
Frank, R. N. 515
Fraser, R. J. 675
Freychet, P. 411
Freyschuss, U. 470
Frighi, V. 278, 371
Froment, V. 465
Fujimoto, W. Y. 489
Fuller, J. H. 477, 538, 542
Funder, J. 619
Furuta, H. 118

G

Gale, E. A. M. 635
Gardais, E. 425
Garg, S. 444
Garrido, M. C. 278, 371
Garrino, M. G. 145
Garros, B. 465
Gebre, P. 222
Gebriel, Z. W. 222
Gentile, S. 272
Ghatei, M. A. 115, 306
Ghirlanda, G. 726
Gilbey, S. G. 115
Gilcrease, M. Z. 329
Gilmore, J. E. 350
Giroix, M.-H. 654
Giugliano, D. 163, 205
Glaser, B. 482
Gleichmann, H. 731
Goldman, A. 593
Gould, B. J. 208
Grankvist, K. 127
Greco, A. V. 726
Greenbaum, C. 638
Grémeaux, T. 24
Gros, F. 661
Gubler, M. C. 661
Guillaume, Gentil, C. 137
Guilluy, R. 449

H

Hägg, E. 244
Halban, P. A. 77, 457
Hales, C. N. 532, 631
Hanafusa, T. 105, 503
Handberg, A. 625
Hanley, S. P. 311
Hanson, U. 100
Harding, P. E. 675
Hardisty, C. A. 177
Hari, J. 266
Harling, H. 403
Harrison, L. C. 641
Hartling, S. G. 36
Hashimoto, M. 597
Hatamori, N. 266
Hayakawa, M. 266
Hayashi, T. 192
Hayes, J. R. 350
Head, J. 477, 538, 542
Heaton, D. A. 497
Heding, L. 384
Heinemann, L. 384
Heller, S. R. 216
Hellerström, C. 1, 447
Hendra, T. J. 532
Henquin, J. C. 145
Herrera, J. 422
Heylen, L. 649
Hirayama, J. 118
Hockaday, T. D. R. 371, 417
Holst, J. J. 403
Hommel, E. 619
Hoops, S. L. 444
Hoover, R. L. 329
Horowitz, M. 675
Hors, J. 425
Hother-Nielsen, O. 603
Hougaard, P. 31
Hudson, B. G. 704
Huff, J. K. 704

I

Iavicoli, M. 688
Ide, M. 250
Ihm, S. H. 709
Ilonen, J. 357
Inada, M. 105
Ionescu, E. 137
Iori, E. 228
Itoh, N. 105, 503

J

Jackson, C. A. 208
Jacobs, K. H. 387
Jansson, P.-A. 253
Jarrett, R. J. 538, 542
Jeanrenaud, B. 137
Jenkins, D. 387
Jensen, I. 384
Jensen, J. S. 619
Johnson, A. 93
Jung, R. T. 43
Jungmann, E. 65

K

Kahn, C. R. 77
Kaiser, N. 482
Kajio, H. 363
Kalits, I. 346
Kandolf, R. 290
Katrak, A. 417
Katsura, H. 105, 503
Kawata, S. 105
Keen, H. 222, 538, 542
Kemmer, F. W. 696
Kern, T. S. 522
Kerr, D. 216
Kidron, M. 197
Kimura, I. 72
Kimura, M. 72
King, H. 3
King, R. H. M. 611
Kino, K. 713
Klein, R. L. 299
Knip, M. 357
Knowler, W. C. 285, 438
Ko, K. 713
Kobayashi, T. 363
Koch, M. 719
Kohner, E. M. 262
Koivisto, V. A. 168
Kolaczynski, J. 168
Kolb-Bachofen, V. 15
Kolb, H. 573, 638
Kono, N. 105, 503
Kosaka, K. 363
Krishnamoorthy, R. 174
Krug, J. 635
Kruszynska, Y. T. 77, 396
Kubar, J. 411
Kuglin, B. 638
Kühl, C. 31
Kurtz, A. B. 60

L

Lam, H.-C. 306
Lampeter, E. F. 635
Landau, H. 482
Landin-Olsson, M. 561
Lavergne, C. 586
Laville, M. 449
Le Marchand-Brustel, Y. 24, 411
Lee, K. U. 709
Lefèbvre, P. 163, 205, 511
Lefèbvre, P. J. 272
Leiter, E. H. 84
Leonetti, D. L. 489
Lepeintre, J. 457
Lernmark, Å. 561, 638
Leslie, R. D. G. 497
Lestradet, H. 425
Letanoux, M. 671
Leuenberger, P. M. 137
Levander, S. 152
Levin, S. 431
Lévy-Marchal, C. 174, 465
Lilja, B. 148
Lindgärde, F. 526
Lindgren, M. 319
Lins, P. E. 152
Lisato, G. 228, 688
Llewelyn, J. G. 611
Lönnroth, P. 253
Lopes-Virella, M. F. 299
Luzi, L. 549
Lye, R. H. 311
Lyons, T. J. 299

M

Macdonald, I. A. 216
Maclaren, N. K. 638
Maddox, A. F. 675
Maeda, Y. 597
Maher, F. 641
Maher, V. 93
Maifreni, L. 228, 688
Malaisse, W. J. 654
Malik, R. A. 311
Mamo, J. C. L. 339
Mandrup-Poulsen, T. 15
Manhem, P. 148
Mansfield, K. 635
Marcelli-Berge, A. 425
Marchi, E. 163, 205
Marelli, C. 131
Marini, P. 131
Marot, I. 24
Marshall, S. M. 334
Martin, S. 15
Martin Serrano, R. 422
Masson, E. A. 311
Mathiesen, E. R. 619
McArthur, R. G. 569, 709
McCormack, J. G. 396
McDuffie, M. 444
McGill, M. 290
McIntyre, N. 396
McKinlay, S. M. 378
Mengesha, B. 222
Messell, T. 403
Michelsen, B. 357
Michiels, B. 187
Mijovic, C. 387
Milani, M. R. 205
Minuesa Asensio, A. 422
Miyagawa, J. 105, 503
Miyazaki, A. 105, 503
Mizumoto, K. 713
Mølsted-Pedersen, L. 31
Moehring, J. 593
Molenaar, J. L. 731
Morinaga, S. 363
Mornex, R. 449
Moroż, C. 557
Morris, A. H. C. 262
Morrish, N. J. 538, 542
Moy, C. S. 422
Muddle, J. R. 611
Mühlhauser, I. 121
Murase, T. 363

N

Nagata, M. 266
Nagataki, S. 597
Nagi, D. K. 532
Naik, S. S. 417
Nakagawa, C. 105, 503
Nakanishi, K. 363
Nakanishi, T. 597
Nanjo, K. 118
Neely, R. D. G. 681
Nelson, R. G. 438
Nerup, J. 15
Newell-Morris, L. L. 489
Nezzer, T. 285
Ng, L. L. 278, 371
Nilsson, K. O. 561
Nishi, M. 628
Nishimura, S. 118
Niskanen, L. 237
Nørgaard, K. 407, 619
Normand, S. 449

O

Ørskov, H. 334
O'Brien, D. 444
Ogawa, W. 266
O'Halloran, D. J. 306
Okamoto, H. 250
Olsson, T. 244
Onodera, T. 192
Östenson, C.-G. 403
Otsuka, A. 105, 503
Owens, D. 93

P

Pachiaudi, C. 449
Pai, V. R. 417
Pak, C. Y. 569
Palmer, J. P. 60, 638
Pampfer, S. 187
Paolisso, G. 272, 511
Papoz, L. 465
Parving, H.-H. 619
Penttilä, I. 237
Perriello, G. 52
Persson, B. 100, 470
Pettitt, D. J. 438
Piddington, R. 593
Pipeleers, D. G. 649
Podar, T. 346
Porciatti, V. 726
Portha, B. 654
Portwood, N. D. 325
Pozza, G. 549
Pozzilli, P. 635
Puhakainen, I. 168
Pyke, D. A. 497
Pyörälä, K. 237

Q

Quatraro, A. 163, 205

R

Rabinovitch, A. 506
Rai, R. 158
Rajotte, R. V. 569
Rayman, G. 631
Reach, G. 457
Reijonen, H. 357
Rennie, M. J. 43
Riccio, A. 228, 688
Riou, J. P. 449
Robert, J. J. 425
Rochet, N. 24, 411
Rohner-Jeanrenaud, F. 137
Rooney, D. P. 681
Rosen, I. 319
Rosselin, G. 586
Rothe, H. 573
Rudberg, S. 470
Rungger-Brändle, E. 137
Ryder, R. E. J. 177
Ryle, A. J. 208, 532

S

Saad, M. F. 285, 438
Sadoul, J. L. 411
Sælan, H. 407
Sahasrabudhe, R. A. 417
Sai, P. 9
Sanke, T. 118
Santeusanio, F. 52
Sarlund, H. 237
Sarras, M. P., Jr. 704
Sato, M. 192
Sawicki, P. T. 121
Scheen, A. 272, 511
Schleret, Y. 465
Schneider, A. E. 532, 631
Schöffling, K. 65
Schönke, H. 290
Schwartz, R. 378
Secchi, A. 549
Segain, J. P. 9
Sener, A. 654
Sergi, G. 228
Serrano, Ríos, M. 422
Serreze, D. V. 84
Sgambato, S. 272
Sharma, A. K. 311

Shattlock, M. A. 731
Shelgikar, K. M. 417
Sheridan, B. 681
Shii, K. 266
Shimizu, K. 713
Shimizu, S. 192
Shinji, Y. 105
Shultz, L. D. 84
Shuman, W. P. 489
Signore, A. 635
Siitonen, O. 237
Simmons, D. 278, 371
Slama, G. 671
Smith, K. 43
Smith, U. 253
Snorgaard, O. 36
Sodoyez-Goffaux, F. 719
Sodoyez, J. C. 719
Sondag, D. 719
Sone, T. 713
Sönksen, P. H. 158
Sonnenberg, G. E. 696
Sowa, R. 118
Spotti, D. 549
Stahl, E. 65
Starke, A. A. R. 384
Staudacher, C. 549
Steiner, D. F. 628
Steiner, G. 339
Stenberg, G. 319
Stenman, U.-H. 378
Stevens, L. K. 538, 542
Sugimoto, T. 363
Sullivan, P. M. 262
Sumoski, W. L. 506
Sundkvist, G. 148, 561
Swanston-Flatt, S. K. 462
Szeto, L. 339
Szopa, T. M. 325

T

Tabata, H. 118
Taddesse, A.-S. 222
Tahara, D. 597
Takahashi, K. 306
Taki, T. 266
Täljedal, I.-B. 127
Tallroth, G. 319
Tames, F. J. 257
Tamura, S. 105
Taniguchi, H. 266
Taniguchi, T. 192
Tanti, J. F. 411
Tarui, S. 105, 503
Tattersall, R. B. 216
Taylor, K. W. 325
Temple, R. C. 532
Teramo, K. A. 378
Terazono, K. 250
Thomas, P. K. 611
Thunell, S. 100
Tichet, J. 174
Tiengo, A. 228, 688
Tissot, S. 449
Tomás Labat, M. E. de 422
Tomkin, G. 93
Tomlinson, D. R. 311
Torlone, E. 52
Triban, C. 131
Trimble, E. R. 681
Tsunoo, H. 713
Tur-Sinai, A. 482
Turner, R. C. 285

U

Uchiyama, Y. 250
Uren, C. 285
Urga, K. 222
Uusitupa, M. 237

V

Vaag, A. 625
Vallet-Colom, I. 174
Van den Brande, J. L. 649
van Lieshout, J. J. 182
Van Obberghen, E. 24, 411
Van Schravendijk, C. F. H. 649
Vanderheyden, I. 187
Varricchio, M. 272
Vercheval, M. 187
Vialettes, B. 411
Vigili de Kreutzenberg, S. 228, 688
Viitanen, M. 244
Vinten, J. 625
Virkamäki, A. 168
Voirin, J. 465
Voutilainen, E. 237
Voutilainen, P. 378

W

Wahl, P. W. 489
Walther, R. 737
Ward, T. 325
Watanabe, J. 713
Watanabe, T. 250
Watkins, P. J. 611
White, M. F. 77
Widness, J. A. 378
Wieling, W. 182
Wieslander, J. 661
Wilkin, T. J. 60
Williams, A. J. K. 635
Willig, J. 112
Woehrle, M. 112
Wogensen, L. D. 15
Worku, Y. 222
Wredling, R. 152

Y

Yajnik, C. S. 417
Yamada, K. 105
Yamagata, K. 105, 503
Yamaguchi, Y. 597
Yamaji, T. 713
Yamamoto, H. 250, 597
Yamamoto, K. 503
Yamaoka, K. 713
Yamasaki, H. 597
Yamashita, A. 713
Yki-Järvinen, H. 168, 579
Yokono, K. 266
Yonekura, H. 250
Yoon, J. W. 569, 709
Yoshihara, K. 192
Yudkin, J. S. 208, 532

Z

Zarandieta Romero, G. 422
Zarrouk, D. 174
Zeuzem, S. 65
Zhang, N. L. 515
Zhang, X. 704
Zirinis, P. 671
Ziv, E. 197
Zoltobrocki, M. 65
Zühlke, H. 737
Zurlo, F. 228

Subject index

KEY: A = abstract (in Supplement), b = Book review, c = Correspondence, r = Review or Debate, w = Workshop or study group report

A

α-adrenoceptor - islet - sulphonylurea, role in 145
α-glycosidase inhibitor - acarbose 24
Abortion - spontaneous - maternal diabetes control 100
ACE (angiotensin-converting enzyme)
- inhibitor [see also Kidney; Microalbuminuria; Nephropathy]
- - captopril - protein glycation, effect on A46
- - diabetes, use in 121r
- - - children 126c
- - enalapril 470
- - microalbuminuria, effect on - mechanism 470
- - - prospective study A75
- - ramipril - glucose metabolic effects A145
Acipimox [see Lipolysis - inhibitor]
Adipocyte - phospholipase C, insulin -dependent - phorbol ester TPA A227
Adipose tissue - arachidonic acid - Type 2 diabetes A211
- brown - function - MRI in vivo A215
- insulin, effect of in vivo A209
- lactate production - microdialysis 253, 740c, 741c
Adrenoceptor [see α-adrenoceptor, β-adrenoceptor]
Advanced glycation end-product; A G E [see Glycation - end product]
Age - glucose homeostasis and A210
Agrimony 462
Air travel - insulin adjustment A116
Albumin excretion rate [see also Somatostatin - analogue; Aldose reductase]
- blood pressure and - Type 2 diabetes A49
- diabetes - metabolic control and A143
- - hypertension and A201
- measurement - albumin:creatinine ratio - Pima A147
- progression - diabetes - lipid composition A154
Albuminuria - diabetes - mortality 542
- Type 2 diabetes - implications A48
Alcohol - hypoglycaemia - unawareness 216
Aldose reductase - cellular osmoregulation, role in A150
- inhibitor - albumin excretion rate - diabetic rat A65
- - diabetic neuropathy, use in 431
- - diabetic retinopathy A89
- - glucose-induced embryopathy, effect on 597
- - nephropathy, galactosaemic 515
- - renal hypertrophy - galactosaemic rat A65
- - sorbinil 515
- - tolrestat 431
- nerve - *db/db* mouse 131
Aldosterone [see Renin]
Alfalfa 462
Alloxan - islet blood flow, effect on A107
- low-dose - diabetes - cyclosporin A A195
- obesity, effect on - mice 24
Amino-acid - disposal - adrenaline, effect of A223
- infusion - skeletal muscle protein synthesis 43
Amylin (Islet amyloid peptide) [see also CGRP]
- assay 118
- CGRP receptor, interaction with A112
- circulating - haemodialysis and A111
- - diabetes - Type 1 & Type 2 A39
- - - Type 2 115
- gene sequence - Type 2 diabetes in Pima Indians 628
- glucose tolerance, acute effect on - dog 118
- - man 115
- islet - B-cell mass and function - diabetic monkey A111
- - intracellular distribution A111
- - Type 2 diabetes A111
- - - Pima Indians 285
- islet hormone release, effects on A40
- metabolic effect - liver - rat A39
- - skeletal muscle - human A40
- pancreas - diabetes - Type 1 & Type 2 A39
- rat - distribution and binding A39
Androgen - dehydroepiandrosterone - glucose metabolism - Type 2 diabetes A134
Angiotensin [see also Renin]
- converting enzyme [see ACE]
ANP (atrial natriuretic peptide) [see also Sodium - retention]
- diabetes A155
- resistance - Type 1 diabetes A67
Antibody - cytomegalovirus - monoclonal 569
- insulin - auto- - assay - 3rd international workshop 60w
- - - - radioimmuno- - Type 1 diabetes A49
- - - - standardisation 638w
- - - clonally restricted 719
- - - islet-cell antibody and - Type 1 diabetes A50, A183
- - - prevalence - normal 719, A49
- - - thyroid disease A183
- - - Type 1 diabetes A25, A182
- - CSII and A182
- insulin-receptor 411
- interleukin-2-receptor - streptozotocin diabetes 266
- islet-cell - 64kD fragment specificity - Type 1 diabetes A192
- - antigen - fucogangliosides A50
- - - CMV-induced antibody reactivity 569
- - - ganglioside? A191
- - - heat shock protein 65 A83
- - - heat stability A191
- - assay - quality control & standardisation 731
- - cytomegalovirus-induced 569
- - exocrine antibody - cytokeratin 363
- - IgG subclasses A50
- - insulin autoantibody and - Type 1 diabetes A50
- - stimulating - insulin gene expression, effect on A36
- - surface - flow cytometry A182
- - Type 1 diabetes - family study 557
- - - insulin dose assessment 561
- nerve - autonomic neuropathy A33
- pancreatic exocrine cell - cytokeratin antigen 363
- proinsulin - auto- - Type 1 diabetes A182
- ssDNA - diabetes - vascular complications and A170
Antihyperglycaemic agent [see Hypoglycaemic agent]
Antiport, Na^+/H^+ - diabetic nephropathy 278
- leucocyte - diabetic nephropathy 371
- platelet - diabetes A74
- protein kinase C, role of 278
Antithrombin - III - hyperglycaemia, effect of 163
Apolipoprotein - plasma - insulin effect, endogenous *vs* exogenous A206
- AI-CIII-AIV gene cluster A82
Artery - calcification - diabetes A169
ATPase - Na^+,K^+ - nerve - *db/db* mouse 131
Atrial natriuretic peptide [see ANP]
Autonomic neuropathy [see Neuropathy - autonomic]

B

B-cell [see B-cell, pancreatic; Lymphocyte - B]
B-cell, pancreatic [see also Insulin; Insulinoma cell; Proinsulin]
- adrenergic inhibition - calcium current and A27
- adrenoceptor - $\alpha 2$ subtypes - rat A28
- - blocking agents, action of A28
- Ca^{2+}/calmodulin-dependent protein kinase A88
- calcium [see also Islet, pancreatic - calcium]
- - channel - L-type - cAMP effect A104
- - cytosol - quinine effect A103
- - - sulphonylurea effect A103
- - mitochondrial - effects A106
- - Na^+ exchange - electrical effect A104
- - oscillations A63
- - - action potential and A103
- - - amines, effect of A102
- - - diabetogenic agents, and A102

- - - temperature, effect of A102
- - protein kinase C effects A63
- Cl^-/cation co-transport A103
- clusters - calcium oscillations - propagation A64
- D-glucose, effect of - mitochondrial oxidation 654
- differentiation - growth hormone, effect of A108
- - mouse A108
- fetal - human - isolation A109
- glucose metabolism - streptozotocin, effect of 654
- GTP-binding proteins A87
- IGF-I, effect of 649
- insulin, effect of 649
- interleukin-1ß, effect of A36
- junction proteins A109
- K^+-ATP channel - Mg^{2+}ADP complex, control by A105
- - ADP binding site and A78
- - perforated patch recordings A78
- Krebs cycle activation A88
- leucine metabolism - streptozotocin, effect of 654
- maturation 482
- microfluorimetry A87
- perifused - rat - IGF-1 and insulin effects 649
- phospholipid synthesis A106
- reg protein synthesis 250
- replication - ßTC1 model 586

Basement membrane [see also Capillary; Endothelium; Microangiopathy; Retina]
- glomerular - glycation - acarbose, effect of A149
- glucose, effect of - *Hydra* model 704
- mesangial - glucose, effect of A149

ß-adrenoceptor - islet - sulphonylurea effect, role in 145

Biguanide - metformin - adipocyte, effect on - *fa/fa* rat A225
- - amino acid metabolism, effect on A126
- - antihyperglycaemic mechanism A126
- - glucose transport, effect on - skeletal muscle A52
- - insulin resistance, effect on - normal man A127
- - lactate turnover, effect on - Type 2 diabetes A52
- - lipid effects A205
- - muscle glycogen synthase, effect on A126
- sulphonylurea, combined with - metabolic effects A125

Biostator [see Clamp]

Blood [see also Erythrocyte; Leucocyte; Platelet]
- coagulation [see also Platelet; Fibrinolysis; Glycation]
- - antithrombin-III - diabetes 163, A74
- - - heparin cofactor-II activity 205
- flow - laser Doppler velocimetry - retina 262
- - skin - diabetes A170
- pressure [see also Hypertension]
- - ambulatory - diabetes A201
- - circadian variation - autonomic neuropathy A33
- - exercise, response to - diabetes A201
- - insulin resistance and - Type 2 diabetes A21
- - Type 2 diabetes - split proinsulin and 532
- viscosity - diabetic nephropathy and 576c

Body - fat - distribution - insulin effect, regional variation A219

Bone mineral density - diabetes A173, A174

Book review 577b, 708b

Breast-feeding - Type 1 diabetes protection? A197

C

C-peptide - glucose transport, effect on A226
- insulin dose assessment 561
- pregnancy, early in diabetes 100
- proinsulin ratio - Type 1 diabetes immunotherapy, in 36
- coronary disease risk factor 489

Cachexia, diabetic neuropathic - malabsorption-induced? A161

Calcitonin-gene-related peptide [see CGRP]

Calcium - cytosolic [see B-cell, pancreatic; Islet; Insulinoma-cell]
- intracellular - aequorin-luminescent transient 72
- metabolism - diabetes A173

Calorimetry - indirect 549

Capillary - endoneural - morphometry - diabetic neuropathy 611
- function in diabetes - acetyl-L-carnitine A175
- - D-*myo*-inositol-1,2,6-triphosphate A175
- glucokinase-like enzyme - eel A220

Cardiovascular risk factor - diabetes - intervention study A204
- hyperinsulinaemia A90, A171
- insulin resistance - rheumatoid disease, in A91
- lipoprotein fractions - diabetes A199
- Type 2 diabetes 542
- - insulin-like molecules 532

Carnitine-acyl transferase inhibitor - etomoxir - insulin binding A230
- - Type 2 diabetes A45

Cassava A79

Cataract [see also Lens]
- advanced glycation end-products A47

Cerebrovascular - incident [see Stroke]

CGRP (Calcitonin-gene-related peptide) [see also Amylin]
- insulin resistance induced by A113
- islet, effect on - cAMP content A112

Chiropody [see Foot]

Cholesterol [see also Lipoprotein; Cardiovascular risk factor]
- cellular - regulation - Type 2 diabetes 93
- synthesis - cellular - LDL composition, effect of 93

Cholesterylester transfer protein - smoking and diabetes effects A204

Chromatography - gas - isotope ratio mass spectrometry - ^{13}C-glucose 449
- liquid - fast - endothelin 306
- - high-performance [see HPLC]

Chromogranin A - pancreastatin sequence 403

Cirrhosis, hepatic - amino-acid turnover A222

Clamp - euglycaemic hyperinsulinaemic - dog 118
- - glucose tracer impurity error 681
- - indirect calorimetry and 549
- - insulin antibodies and A113
- - obese man 228
- - rat 77
- - - fatty acid effect 396
- hyperglycaemic - combined insulin/sulphonylurea treatment 688

Coagulation - blood [see Blood - coagulation]

Coeliac disease - Type 1 diabetes, with A135

Cognitive function - hypoglycaemia - alcohol 216
- hypoglycaemia, following 152
- Type 2 diabetes A41

Collagen - Type IV - immunocytochemistry 661

Colour vision - Type 1 diabetes A88

Complications - diabetes - magnesium and 511r

Computer - diabetes management - personal system A127

Cori cycle 158

Coriander 462

Cornea - autofluorescence - diabetes A156

Countertransport - Na^+/H^+ [see Antiport - Na^+/H^+]
- Na^+/Li^+ - diabetes A12
- - - nephropathy 278, 371
- - - - familial A12
- - - - marker A12
- - - - marker A13
- - - - risk A12
- - - normotensive normoalbuminuric A150
- - nephropathy - not inherited 619
- - hypertension - insulin resistance A151
- - insulin, glucagon, glucose effects A151

CSII [see Insulin - infusion - SC]

Cyclosporin A - B-cell, pancreatic, effect on A38
- - intracellular pH A196

Cystic fibrosis - diabetes in - mechanism A134

Cytokine [see also Interleukin; Mouse - NOD; Rat - BB; Tumour necrosis factor]
- circulating - Type 1 diabetes A25
- insulin secretion, effects on - isolated rat islet A194

D

Dawn phenomenon [see also Insulin - treatment]
- growth hormone spikes and 52
- somatostatin in 52

Death, sudden - diabetic autonomic neuropathy - QT interval A33
- Type 1 diabetes A196

Diabetes - classification - islet-cell antibody and A80

- gestational - glucose tolerance, subsequent A56, A137
- - insulin treatment, prediction of A137
- - plasma membrane effects A137
- - race A136
- - screening - timing A136
- - subsequent diabetes risk A137
- lipoatrophic, acquired - leucine metabolism A223
- malnutrition-related 222
- management [see also Computer;Diet; Education;Insulin;Nurse]
- - Finland A131
- - hospital admission - children A130
- pancreatic - fibrocalculous - cyanide role? A79
- - insulin treatment - multiple injections A115
- Type 1 - age at onset - climate A16
- - animal model [see also Mouse; Rat; Streptozotocin]
- - - reovirus/NC mouse 192
- - Coxsackie B virus 290
- - epidemiology - Estonia 346
- - - France 465
- - - Spain 422
- - - temperature - NOD mouse model 635
- - family study - Tel-Aviv 557
- - genetics - C4B - abnormal genes A43
- - - HLA - diabetes risk - Finland A44
- - - - gene mapping 387r
- - - - - pulsed-field electrophoresis A43
- - - haplotype segregation 425
- - - - DQ 357, A44
- - - - DQA3 A44
- - - - DQB1 - (57) 174
- - - - DQB1 - remission, association with A44
- - - molecular - International Symposium 737w
- - - multiplex family study 425
- - immunotherapy - cyclosporin 36
- - - proinsulin:C-peptide ratio 36
- - nicotinamide treatment 444
- - pancreas - biopsy 105
- - prediction - HLA-DQ B marker 357
- - - host-environmental interactions A16
- - - insulin response - acute A68
- - - IV glucose tolerance test A68, A183, A184
- - - placental isoferritin 557
- - pregnancy, diagnosed in 31
- - prevention - immunology and diet 509w
- - progression - ICA A184
- - - initial C-peptide A183
- - psychological stress as risk factor A128
- - remission - induction - glipizide A184
- - - - intensive insulin therapy A208
- - - stimulated C-peptide response A208
- - treatment [see Hypoglycaemia; Insulin; Education; Exercise]
- Type 2 - aetiology - obese *vs* non-obese A214
- - amylin, circulating 115
- - epidemiology 3r
- - genetics - glucose transporter genes A14, A14
- - insulin treatment - psychological factors A41
- - pathophysiology [see also Glucose; Insulin - resistance]
- - prediction - glucose disposal rate A80
- - - impaired glucose tolerance 526
- - prevention 3r
- - risk factors 3r
- - treatment [see also Biguanide; Diet; Sulphonylurea; Hypoglycaemic agent]
- - - prandial insulin A114
- - - sulphonylurea/insulin combined 688
- virus-induced 192

Diabetologia - 25 years 447

Diet - diabetes - alcohol A133
- - carbohydrate type - insulin sensitivity, effect on A133
- - compliance A132
- - fibre A133
- - formula A132
- - fructose - glucose, conversion to - exercise and A212
- - magnesium 511r
- - obesity A132
- - Ω-3 fatty acids A134
- - Type 1 - questionnaire - bar-code A132
- glycaemic response - preprandial blood glucose, effect of A208
- protein - glucose homeostasis, effect on - Type 1 diabetes A209
- sucrose - *fa/fa* rat - retinopathy 137
- Type 1 diabetes - prevention 509w

Digitalis-like factor - urinary - diabetes A202

Dog - alloxan-diabetic - nephropathy 522

E

EASD - 25th Annual Meeting - Abstracts A11
- - Agenda A10
- 25th General Assembly - minutes A5
- Organisation Section 64, 324, 578, A235
- Study Group - Artificial Insulin Delivery Systems (AIDSPIT/1990) A3w
- - Control of Metabolism (CMSG/1989) A3w
- - Diabetes and Nutrition (DNSG/1989) A2w
- - Diabetes Education (DESG/1989) A4w
- - Diabetic Nephropathy (EDNSG/1990) A1w
- - Diabetic Pregnancy (DPSG/1989) A1w
- - Epidemiology (EDESG/1990) A3w
- - Lipoprotein - preliminary programme A1w

Editorial - Diabetologia - 25 years 447
- To our readers 1

Education - diabetes - health care workers A128
- - primary health care centre - Sweden A40
- - study group A4w
- - Type 1 - compliance A129
- - - locus of control - basal-prandial regimen A129
- - - standardisation and transfer A41
- - Type 2 - insulin treatment decision and A41
- - - modular programme A40
- - videotex system - Minitel A127
- diet - Type 2 diabetes - metabolic control, effect on A41
- HbA_1, value in A136

Electrocardiography [see Death; Neuropathy]

Electroencephalography - hypoglycaemia 319

Embryo - laminin-B1 - maternal diabetes - rat A138
- malformation - glucose-induced - free-radical scavengers and A139
- *myo*-inositol - neural tube fusion 593, 597
- neural tube fusion 593, 597
- preimplantation - maternal diabetes - rat 187

Endothelial cell - glucose, effect of - collagen IV and laminin A148
- glycosaminoglycan metabolism - insulin & cortisol A157
- replication - glucose-inhibited by - L-tyrosine A51

Endothelin - assay - RIA 306
- fast liquid chromatography 306
- I - hepatic glycogenolysis, effect on A221
- plasma - diabetes 306
- - microalbuminuria and - Type 1 diabetes A51
- retinal endothelial cell, production by - glucose effect A51

Endothelium - polyol pathway - sorbitol accumulation and A51
- vascular Na^+/K^+-ATPase, effect on - glucose and A157

Energy - expenditure - Type 2 diabetes A59
- metabolism - Type 1 diabetes - metabolic control, effect of A208

Epidemiology [see also Diabetes - Type 1; Diabetes - Type 2; Mortality]
- diabetes - elderly - Finland A80
- - childhood - Germany A197
- - - Poland A198
- - - sex A197
- - insulin-treated - Estonia 346
- - - Estonia and Finland A17
- - - Europe A17
- - - France 465
- - - Peru A80
- - - seasonality A198
- - - Seychelles 184c
- - - Spain 422
- - Malmo, Sweden 526
- - non-insulin-treated 3r
- study group A3w
- twin study - diabetes concordance - Finnish cohort A57

Erythrocyte - aggregation - diabetes and hypertension A158
- charge A135
- deformability - insulin and 127
- glycophorin sialylation - diabetes A157
- plasma membrane - diabetes, effect of A73

Erythropoiesis - insulin, effect of 127
Erythropoietin - fetal - diabetic pregnancy 378
Ethiopia - malnutrition-related diabetes 222
Etomoxir [see Carnitine-acyl transferase inhibitor]
Eucalyptus 462
Exchange - Na^+/H^+ [see Antiport - Na^+/H^+]
Exercise - aerobic metabolism - Type 2 diabetes A210
- catecholamines - Type 1 diabetes 148, 739c
- CSII management 696
- renin-angiotensin-aldosterone system - Type 1 diabetes 739c, 148, 637
- Type 1 diabetes - blood glucose following A119
Eye [see also Cataract; Colour vision; Cornea; Lens; Retina; Retinopathy]
- physiological changes - Type 1 diabetes, early A88

F

Fat [see also Adipose]
- body - bioelectrical impedence, measurement A199
- - distribution - metabolic features A214
- - metabolic correlates in Type 2 diabetes A212
- intra-abdominal - coronary disease risk factor 489
Fatty acid - insulin sensitivity, effect on - chain length effect A55
- non-esterified - glucose cycle - exercise, role in A46
- - glucose metabolism, effect on - rat muscle 396, A45
- - glycogen synthase, effect on - muscle A46
- - insulin resistance, effect on - nutrition A45
- - obesity 228
- - skeletal muscle uptake A81
- Ω-3 polyunsaturated - insulin binding & action A205
- turnover - obesity 228
Fatty rat [see Rat - *fa/fa*] 137
Feeding - intermittent - islet function, effect on - rat A110
Fertility - diabetes, effect of A140
Fetus - echocardiography - maternal diabetes A55
- erythropoietin - maternal diabetes 378
- islet B-cell maturation 482
- lung maturation - maternal diabetes A138
- malformation - maternal diabetes control 100
- oxygenation - erythropoietin level - diabetic pregnancy 378
FFA [see Fatty acid - non-esterified]
Fibrinolysis - diabetes - Type 1 *vs* Type 2 A158
- glucose, effect of A158
- microalbuminuria and - Type 1 diabetes A52
- plasminogen activator - Type 2 diabetes - fat distrib'n A52
- Type 1 diabetes A74
FK-506 - immunosuppressant 503
Foot [see also Neuropathy; Blood - flow]
- amputation - diabetes - skin oxygenation and arterial pressure A24
- care - chiropodist A24
- - clinic A169
- - limited joint mobility A170
- - multi-disciplinary approach A130
- - onychomycosis A169
- - pressure screening A168
- - ulcer - growth factor therapy A169
- - vascular responses A168
- infection - assessment - immunoscintigraphy A24
- ischaemia - prostacyclin analogue therapy A25
- - thrombolytic therapy A25
Fructosamine assay - orthostasis efect A178
- serum protein concentration correction A177

G

Galanin [see also Mouse - *ob/ob*; Insulin - secretion]
- growth hormonone secretion, effect on - arginine-stimulated A72
- insulin secretion, effect on - arginine-stimulated A72
- pancreas, distribution in - mouse, rat A110
- rat - action in rat 125c
- sympathetic neurotransmitter 125c
Gall bladder function - diabetes A162
Ganglioside - cronassion - islet transplantation 112
Gastric [see Stomach]
Gastrin - plasma - diabetes A163
Gastrin-releasing peptide - islet, effect on A72, A100
Gastroparesis [see Neuropathy - autonomic]
Gene - amplification [see Polymerase chain reaction]
- library, cDNA - islet-derived 250
- *reg* 250
Genetics - apolipoprotein E - diabetes - Italy A204
- diabetes 577b
- - Type 1 - CD3ε A188
- - - complement C4 A83
- - - family study - Finland 357
- - - heat shock protein 70, A83, 73, A83
- - - HLA - China A187
- - - - Class II - multiplex families A188
- - - - DQB - 1(57) - France 174
- - - - - age at onset A188
- - - - - Finland 357
- - - - - protection A187
- - - - gene mapping 387r
- - - - Italy A187
- - - maternal effect 425
- - - tumour necrosis factor ß A83
- - Type 1 and Type 2 diabetes linked? A198
- - Type 2 diabetes - amylin gene A112
- - - amylin gene precursor - Pima Indians 628
- - - GluT 4 A224
- - - parental gender effect A200
- diabetic nephropathy [see also Nephropathy; Microalbuminuria]
- - Pima Indians 438
- molecular - Type 1 diabetes - International Symposium 737w
Glibenclamide [see Sulphonylurea]
GLP, GLIP (Glucagon-like insulinotropic peptide)
- 1 - islet hormone secretion, effect on - mouse A73
- 1(7-36)amide - diabetes, effects on - man A73
- - islet hormone secretion, effect on - mouse A73
- - receptors - insulin-secreting cells A99
- - renal catabolism A218
- 1(78-107)amide - incretin? A99
- plasma - Type 2 diabetes A211
Glomerular, Glomerulus [see also Albumin; Basement membrane; Microalbuminuria; Microangiopathy, Nephropathy]
- basement membrane - galactosaemic rat 515
- charge selectivity - diabetes A67
- filtration rate in diabetes - ACE, effect of 126c
- - factors affecting A66
- - growth hormone A152
- - NAG and transferrin excretion A151
- - natriuretic hormones A152
- - renin-angiotensin system A152
- - somatostatin analogue, effect A76
- selectivity A153
- function - Type 2 diabetes - Pima Indians A48
- polyamine metabolism - diabetic rat A64
- stereological study - diabetes A147
Glucagon - action - age, effect of 272
- - pulsatility, effect of 272
- glucose production, hepatic, effect on - Type 1 diabetes A54
- intranasal lyophylised 671
- liver mitochondria, effect on A222
- secretion - interleukin 1 ß, effects of 15
- - pancreastatin, effect of 403
- - pulsatility - action, effect on 272
Glucagon-like insulinotropic peptide [see GLP]
Glucocorticosteroid - diabetogenesis - insulin response and A59
Gluconeogenesis - hepatic - assessment - acetaminophen glucuronidation A215
- insulin deficiency, in - glucose cycling 158
- substrate - Type 2 diabetes - skeletal muscle A59
- Type 2 diabetes - liver glucose output, role in A211
- - skeletal muscle role A211
Glucose - alanine cycle - man A221
- analogue - 3-o-methyl-D-glucose - neutrophil transport A220
- blood - home monitoring - elderly A128
- - meter - Exactech A118
- cycling [see also Glucose - turnover]

- - insulin deficiency, severe 158
- disposal - adrenaline, effect of A54
- homeostasis - mathematical model - insulin assay and A86
- production - insulin, inhibition by - peripheral in diabetes A77
- - measurement - IVGTT model A215
- - postprandial - gluconeogenesis - Type 2 diabetes A58
- receptor - sweet taste cells and islet B-cells A97
- sensor [see also - blood - meter]
- - intravenous - clinical trial A35
- - IV A117
- - SC A118
- - - interference - acetaminophen (paracetamol) A117
- - subcutaneous - kinetics in dog A35
- tolerance - impaired - cardiovascular risk A58, 489
- - - diabetes progression - age and A57
- - - follow-up - Tanzania A199
- - - HbA1 and 208
- - - risk of diabetes 526
- - - Type 1 diabetes, preceding - twins 497
- - test - IV - reproducibility 631
- - - - standardisation A68
- - - oral - reproducibility 526
- tracer - 1-^{14}C-glucose 158
- - ^{13}C-glucose 449
- - tritiated 158
- - - assay 168
- - - errors A220
- - - primed-continuous method 603
- - [6-^{3}H]glucose - labelled impurity, error due to 681
- transport - adipocyte - ML-9, effect of A226
- - mass action effect 579r
- - measurement - positron emission tomography A23
- - skeletal muscle - hyperglycaemia, effect of A22
- - - Type 2 diabetes A23
- transporter [see also Rat - *fa/fa*; Genetics]
- - adipocyte - translocation A224
- - brown adipose tissue - *ob/ob* mouse A225
- - cardiomyocyte - insulin resistance A225
- - contraction-regulated - skeletal muscle A32
- - expression - diabetes A14
- - - - Type 2 625
- - - hyperthyroidism A225
- - - L6 myocyte 641
- - - skeletal muscle - fasting A23
- - - - diabetes - Type 2 A23
- - - hexoses, effect of 641
- - genetics [see also Diabetes - Type 2; Genetics]
- - GluT1 - L8 myocyte - glucose effect A224
- - - expression - glucose, regulation by A31
- - - mutated - structure-function rel'nship A32
- - GluT4 - expression - insulin and A31
- - - insulin-resistant Type 1 diabetes A22
- - insulin-regulatable - skeletal muscle 625
- - mRNA - β-adrenergic effect A224
- turnover [see also Glucose - cycling]
- - assessment - non-steady state A215
- - basal - primed-continuous tracer method 603
- - growth hormone spikes and 52
- - insulin, effect of - differential A54
- - measurement 168
- - - fructose cycling, effect of A220
- - mild diabetes, normal in A76
- - obesity 228
- - skeletal muscle - rat 396
- - tracer impurity, error due to 681
- - Type 2 diabetes 603
- uptake - adipose tissue 253

Glucotoxicity [see Insulin - secretion - hyperglycemia]

Glycation [see also ACE; Basement membrane; Cataract; HbA1; Fructosamine assay; Lipoprotein; Thrombolytic]
- albumin - peritoneal dialysate, in A177
- end product [see also Cataract]
- - pentosidine, plasma - pentose metabolism and A47
- - receptor - monocyte 329
- fibrinogen - streptokinase-activated fibrinolysis, effect on A46
- haemoglobin [see also HbA_1]
- - δ-gluconolactone, role of A176
- - mathematical model A176
- - variability independent of glycaemia 208
- heparin cofactor II 205
- membrane proteins A177
- protein - captopril, inhibition by A46
- vessel-wall protein - monocyte adhesion 329
- vitamin C, effect of A177
- VLDL - rat 339

Glycogen synthase, skeletal muscle - fatty acid, effect of 396
- - Type 2 diabetes and obesity A213

Glycogenesis - liver A77
- skeletal muscle - amylin and CGRP, effects of A112

Glycolysis - skeletal muscle - fatty acid, effect of 396

Growth - childhood diabetes - microalbuminuria and A31
- factor - epidermal - circulating - diabetes A74
- - epidermal - urinary - diabetic renal disease, in A154
- - insulin-like [see IGF]
- - platelet-derived - circulating - diabetes A74
- hormone - dawn phenomenon, role in 52
- - glucose metabolism, effect on A29, A217, A218
- - glucose/G-6-P cycle, liver, effect on A55
- - nocturnal spikes and glucose metabolism 52
- - release - Type 1 diabetes A218

H

Haemochromatosis, hereditary - diabetes in A58

HbA_1 - assay - enzyme immunoassay A176
- assay - gel electrophoresis - BB rat 257
- blood glucose, relationship with A136
- normal man - variability 208
- pregnancy - early - diabetes 100
- - diabetes - fetal erythropietin 378
- reproducibility A199

Heart - coronary artery disease - diabetes 538, 542
- - silent - diabetes A171
- - risk factor - Japanese-American men 489
- diastolic haemodynamics - diabetes A172, A173
- failure - insulin resistance A216
- function - diabetes - radionucleotide ventriculography A163
- left ventricular function - diabetes A172
- myocardial infarction in diabetes - prognosis A90
- - sex and prognosis A200
- - dog A219
- ventricular arrhythmia in diabetes A172, A172

Heat shock protein - 65 - islet-cell antigen A83
- 70 - gene - Type 1 diabetes A83
- - rat islet expression, IL-1ß-induced A83

Hemo- [see Haemo-]

Herbal remedies - diabetes 462

High-performance liquid chromatography [see HPLC]

History - diabetes 577b

HLA [see also Genetics]

HLA - Class II - regulatory region polymorphism A187
- DQB - Type 1 diabetes - France 174
- gene mapping - Type 1 diabetes 387r
- haplotype segregation - Type 1 diabetes 425

HMG-CoA reductase inhibitor [see also Nephropathy - diabetic]
- simvastatin - erythrocyte tocopherol and A82
- - insulin resist'ce, effect on A53

HPLC (high-performance liquid chromatography)
- insulin - islet xenograft assessment 457
- [6-^{3}H]glucose impurity 681

Hydra vulgaris - basement membrane model 704

Hyperfiltration [see Glomerulus - filtration rate]

Hyperglycaemia - antithrombin II activity, effect on 163
- gastric emptying, effect on 675
- glucose metabolism, effects on 579r

Hyperinsulinaemia - Asian subjects in UK A200
- body fat and A200

Hyperlipidaemia in diabetes [see also HMG-CoA reductase inhibitor]
- cardiovascular risk A90
- intensive insulin therapy A205

- treatment - gemfibrozil A126, A205, A206
- prevention A202

Hypertension [see also Blood - pressure]
- diabetes - mortality 542
- - prostaglandins, angiotensin-II role A151
- - training programme A144
- - treatment - metabolic effects A145
- - Type 1 - prevalence 407
- essential - insulin resistance A22
- genetic - rat - insulin sensitivity A22
- treatment in diabetes - ACE inhibitor A75, 121r
- - β-adrenergic blocker A75
- - thiazide A75

Hypoglycaemia - awareness - alcohol and 216
- - insulin species and A122, A123
- - reduced - counterregulation A122
- blood-brain barrier, effect on A120
- cerebral function - delayed recovery 319
- cognitive function, effect on A84
- counterregulation - catecholamines A118
- - hyperthyroidism, in A119
- - insulin, direct effect of? - rat A54
- - insulin secretion, reduced A119
- - insulin species and A122
- - noradrenergic nerves - pancreas A119
- detection - reaction-time monitoring A121
- exercise-induced - CSII and 696
- hyperinsulinaemic, persistent, of infancy 482
- incidence - Type 1 diabetes A120
- intermittent - conterregulatory hormones A84
- metabolic effects - pancreas/kidney transplant and A85
- neonatal - persistent with hyperinsulinism A108
- neurophysiological changes 31- nocturnal - EEG A121
- - growth hormone secretion and A84
- psychological causes in diabetes A84
- psychological effects A123
- rebound hyperglycaemia A118
- recurrent - glucose transport and A85
- retinal blood flow, effect on 262
- severe - cognitive function, effect on 152
- thermogenesis A120
- treatment - glucagon - intranasal 671, A121
- tumour-associated - IGF-II-producing histiocytoma A121

Hypoglycaemic agent - A41666 (D-phenylalanine derivative) A98
- linogliride - action A104
- oral [see also Obesity - treatment]
- - benfluorex - streptozotocin diabetes A229
- - secondary failure [see also Diabetes - Type 2] 688
- - - insulin resistance and A125
- - SL 84.0418 A123
- - tetrahydrolipstatin? A124
- traditional plant remedies 462

I

IAPP, Islet amyloid polypeptide [see Amylin]

IGF-I (insulin-like growth factor-I; Somatomedin-C)
- glucose uptake, effect on - skeletal muscle - rat A71
- insulin release, effect on 649
- metabolic effect - diabetic rat A71, A228
- - man A71
- mRNA - renal hypertrophy in diabetic rat 334

Immune, Immunity, Immuno [see also Antibody, Cytokine, Lymphocyte, Splenocyte]

Immunocyte - islet cytotoxicity - Type 1 diabetes A26

Immunotherapy - FK-506 - NOD mouse 503
- streptozotocin diabetes - interleukin 2 receptor Ab 266
- Type 1 diabetes 509w, 741c

Impotence, erectile - diabetes A161
- prostaglandin E1 intracavernosal injection A164

Incretin effect - pancreas transplantation, effect of A38
- parasympathetic nervous system and A27

Instructions to Authors, full *Advertisement pages, January and July issues*

Insulin - absorption - ileum 197
- action - magnesium, role of 511r
- analogue - fast [see Insulin - magnesium]
- - metabolic action - glucose tracer study A60
- - pharmacokinetics - receptor affinity and rate A19
- - slow - [Arg^{A0}]-human insulin-(B30-amide) A117
- - - Di-Arg(31-32) 65, 384, A60
- assay - homeostasis model assessment, importance in A86
- - immunoradiometric A86
- - insulin-like molecules and 532
- biosynthesis - enkephalin, effect of - rat islet A93
- - G-6-P liposomes, effect of - rat islet A93
- - hyperglycaemia, effect of - rat A94
- - mouse insulins I and II - mRNA *vs* plasma levels A94
- - Na butyrate,effect of - RINm5F cell A93
- - release, balance with - measurement A94
- delivery system - artificial - study group A3w
- erythropoiesis, effect on 127
- gene expression - enhancer - rat NHI-6F cell-line A37
- - transgenic mouse A36
- infusion - device - implantable - multicentre study A34
- - intraperitoneal A114, A207
- - pulsatile A35
- - SC - exercise and 696
- injection - absorption - delayed - analogue study A61
- - basal/prandial - bedtime - low dose A115
- - - bedtime - Monotard *vs* Ultralente A115
- - - prandial - timing A116
- - disappearance rate - site, effect of A60
- - once daily - Type 2 diabetes A116
- intranasal - phospholipid absorption enhancer A61
- IV - infusion - osmotic minipump 257
- -like growth factor [see IGF]
- magnesium A117
- obesity, action in 228
- oral - intestinal absorption - rat ileal preparation 197
- plasma - pulsatility - mathematical model A85
- protein synthesis, effect on - man 43
- receptor - autoantibody - Type 1 diabetes 411
- - β-subunit - C-terminus 77
- - conformational change on binding A20
- - diarginyl insulin binding 65
- - gene - polymorphism - Type 2 diabetes A79
- - - Type A insulin resistance, deletion in A227
- - IGF receptor compared A226
- - IM-9 lymphoblastoid cells - heterogeneity A228
- - insulin, regulation by - binding site number A226
- - internalisation - Type 2 diabetes A20
- - negative cooperativity - insulin dimerisation A227
- - renal tubular recycling A20
- - second messenger - magnesium 511r
- - tyrosine kinase - acarbose, effect of 24
- - - activation by insulin 77
- - - α-subunit structure and A20
- - - substrate - annexin A227
- release - Coxsackie B4 virus 325
- - galanin, effect of - G-protein role A27
- - hexadecylphosphocholine, effect of - mouse islet A97
- - IGF-I, effect of 649
- - insulin, effect of 649
- - persistent hyperinsulinaemic hypoglycaemia of infancy 482
- - pH, intracellular, and A97
- - prostaglandin role A97
- - protein kinase A and A107
- - sulphonylurea-induced 145
- resistance - acarbose, effect of - obese mouse 24
- - acidaemia, effect of - rat A217
- - amylin and 118, 285
- - cardiovascular risk factors and A57
- - essential hypertension - ACE inhition in A91
- - glucocorticoid receptor blocker RU 486, effect of A230
- - glucose and insulin, induction by - rat muscle A29
- - growth hormone, nocturnal 52
- - hyperglycaemia-induced 579r, A76
- - inheritance - Pima Indians A56
- - lactate metabolism - hepatocyte A28
- - lipid oxidation, effect of - skeletal muscle A29
- - motor neurone disease A217
- - nocturnal [see also Dawn phenomenon]
- - pancreas & renal transplantation, effect of 549

- - vanadate, effect of - rat A71
- response - first-phase [see Glucose - tolerance - test - IV]
- SC - resistance to A113
- secretion [see also B-cell, pancreatic; Insulin - release; Insulinoma cell; Islet; Pancreas]
- - acyl-CoA esters, effect of - HIT cells A106
- - arginine, effect of A95
- - ATP, extracellular, effect of A101
- - feedback inhibition by insulin - Type 2 diabetes A86
- - food-induced [see Incretin effect]
- - galanin, role of - human islet A100
- - GLIP, effect of A101
- - hyperglycemia, prolonged, effect of A95, A96, A72
- - interleukin 1ß, effects of 15
- - neurally-stimulated - adrenoceptor role A99
- - neuropeptide Y, effect of A99
- - pulsatility - obesity A85
- - vasopressin, effect of A101
- sensitivity - transcapillary insulin transport and A59
- treatment - air travel A116
- - dawn phenomenon [see Dawn]
- - hypoglycaemia [see Hypoglycaemia]
- - initial dose assessment - C-peptide & ICA 561
- - intensive [see also Insulin - infusion; - inj'n]
- - - insulin secretion, effect on A116
- - sulphonylurea, combined with 688
- U100 - Seychelles 184c

Insulinoma cell - HIT T15 - K^+ channel - Ca-activated A105
- RINm5F - Ca^{2+} uptake, microsomal - monoclonal Ab A102
- - calcium - glucose-induced changes - localis'n A64
- - depolarisation - ATP, external, induced by A102
- - glucose transport - glucose,regulation by A36
- - immune adherence to 9
- - K^+ channel - voltage-gated A104
- - neoantigen expression - human complement-receptor A82
- ßTC1 - cell cycle 586
- - oncogene expression 586

Insulitis [see also Mouse - NOD; Rat - BB; Streptozotocin]
- BB rat - theophylline effect 506
- Coxsackie B myocarditis - VP1 capsid antigen 290
- marker in vivo - labelled IL-2 - NOD mouse A62
- NOD mouse - FK-506, effect of 503
- Reovirus Type 2 - mice 192
- Type 1 diabetes - VP1 Coxsackievirus capsid antigen 290

Interleukin - 1ß - insulinoma cell toxicity - glucokinase, effect on A18
- - islet B-cell suppression - glucocorticoid effect A193, A194
- - - cytosolic sodium A19
- - - nicotinamide effect A18
- - - poly(ADP-ribose) synthetase A19
- - pancreas, effect on 15
- 2 - production - *o*-3 polyunsaturated fatty acids and A185
- - - Type 1 diabetes A185
- - receptor - antibody - streptozotocin diabetes 266
- - - Type 1 diabetes A25
- - - - relatives A26
- insulinoma cell line, release by A18
- islet-cell killing by macrophages, role in A18

Intestine - glucose utilisation - diabetic rat - gliclazide & insulin A228
- insulin absorption 197

Ionic flux [see Antiport, ATPase, Countertransport]

Islet, pancreatic - adenine nucleotide pattern - fed *vs* starved rat A106
- calcium - oscillations A63
- cell - individual - enzyme activity measurement A107
- - precursor A109
- culture - human infant 482
- electrically permeabilised - Ca^{2+}-dependent protein kinase loss A107
- function - tropical calcific pancreatitis 417
- glucose-6-phosphatase - rat A105
- hormone secretion - ßadrenoceptor role A100
- - GABA role A100
- immunohistochemistry - Type 1 diabetes 105
- isolated - mouse - adrenoceptor role 145
- microencapsulation - alginate-polylysine - host responses A181
- - barium alginate A42
- mouse - insulin release - Coxsackie B4 virus effect 325
- regeneration - poly(ADP-ribose) synthetase inhibitor 250
- - reg protein 250

Islet amyloid peptide [see Amylin]

Islington Diabetes Survey 208

Isoferritin - placental - Type 1 diabetes family study 557

J

Joint mobility, limited - diabetes - microangiopathy and A174

Juniper 462

K

Ketogenesis - adrenaline-induced - hyperinsulinaemia prevents A207

Ketonaemia - substrate metabolism, effect on - Type 1 diabetes A207

Kidney [see also Albumin; Basement membrane; Glomerulus; Microalbumin; * Nephropathy; Transplantation]
- basement membrane - collagen - streptozotocin diabetes 661
- basolateral membrane - Ca^{2+} transport - insulin and diet effect A150
- function - diabetes - ACE inhibitor - ß-blocker compared A144
- - - calcium antagonist effect A144
- - - isotope renogram A142
- - - protein, dietary, reduced A143
- hypertrophy [see also Somatostatin; Aldose reductase - inhib'r]
- - diabetic rat - IGF-I mRNA 334
- - sodium restriction, prevention by - diabetic rat A64
- IGF-I binding - diabetic rat A148
- kallikrein-kinin system - Type 1 diabetes A153
- macula densa - insulin, effect of - diabetic rat A149
- Tamm-Horsfall glycoprotein - Type 1 diabetes A152
- - localisation - diabetic rat A148

L

Lactate - adipose tissue, production by 253, 740c, 741c

Laminin - urinary - blood pressure relationship - diabetes A154

Langerhans cell - Type 1 diabetes A186

Laparoscopy - pancreas biopsy 105

Laser - Doppler velocimetry - retina 262

Lens [see also Cataract]

Lens - diabetes - aldose reductase inhibitor effects A69

Leucocyte - aggregation - Type 1 diabetes A73
- pH, intracellular 278, 371
- neutrophil [see also Phagocyte]
- - function - diabetes A175
- - - insulin, effect of A195

Ling Zhi-8 - NOD mouse, effect on 713

Lipaemia - postprandial - diabetes A203

Lipid - metabolism [see also Carnitine-palmitate transferase]
- transport - diabetes A202

Lipolysis inhibitor - acipimox - muscle glucose metabolism, effect on A45
- - Type 2 diabetes A81

Lipoprotein - fractions - cardiovascular risk - diabetes A203
- HDL - 2 - insulin resistance and A203
- - Type 2 diabetes - split proinsulin and 532
- LDL - cholesterologenesis, effect on - Type 2 diabetes 93
- - composition - triglyceride, effect of A203
- - esterified:free cholesterol ratio 93
- - glycation - carboxymethylated product - catabolism A47
- - Type 2 diabetes - metabolism - macrophage 299
- serum - microalbuminuria - Type 1 diabetes - good control A81
- - Type 2 diabetes - microalbuminuria and 237
- study group A1w
- VLDL - catabolism - glycation, effect of 339
- - glycation - metabolic effect 339
- - insulin binding A204
- - subfractions - Type 1 diabetes A81
- - tracer - ^{131}I-B-apoprotein 339
- - - tritiated oleic acid 339

- - Type 2 diabetes - metabolism - macrophage 299
Lung - alveolo-capillary permeability - diabetes A175
Lymphocyte [see also Immunocyte; Insulitis]
- B - $CD5^+$ - circulating - Type 1 diabetes A26
- rosette-forming - streptozotocin diabetes 9
- T - islet β-granule specificity - Type 1 diabetes A186
- - islet-B-cell-adherent - Type 1 diabetes risk A26
- - Ling Zhi-8, effect of - NOD mouse 713
- - lymphokine production - Type 1 diabetes A185
- - placental isoferritin as marker 557
- - subpopulations - prediabetes Type 1 A186
- - - Type 1 diabetes families A185
- - NOD mouse 84

M

Macrophage [see also Interleukin; Phagocyte]
- lipoprotein metabolism - Type 2 diabetes 299
- TNFα secretion - BB rat 573
Macrovascular disease - apolipoprotein gene-cluster RFLP A82
- cerebral [see also Stroke]
- diabetes A171
- diabetes - endothelin, possible role of 306
- - mortality 477, 538, 542
Magnesium - glucose homeostasis, role in 511r
Malformation - congenital - diabetic rat 187
Malnutrition - diabetes 222
- pancreatic B-cell mass, effect on - rat A110
Mass spectrometry - gas chromatograph isotope ratio - ^{13}C-glucose 449
Metabolic control - BB rat 257
- diabetic glomerulopathy, effect on - dog 522
- study group A3w
MHC [see also Genetics; HLA]
- Class I - expression - insulin-producing cells A195
Microalbuminuria - ACE inhibitor, effect of 470
- assay - dip-stick A147
- diabetes - Asian patients - implications A142
- - Type 1 - acetylator phenotype and A30
- - - childhood A30, A140
- - - cold pressor test response in A143
- - - growth disturbance and A31
- - - prevalence A140, A141
- - - puberty A141
- - - risk factors A141
- - - transcutaneous oximetry A143
- - Type 2 - cardiovascular risk factors and A48
- - - mortality A49
- lipoproteins and - Type 2 diabetes 237
- macrovascular disease and - Type 2 diabetes 237
Microangiopathy - diabetic - genetic factor A66
- *fa/fa* rat model 137
- Type 1 diabetes - factors affecting development A69
Microdialysis - adipose tissue 253, 740c, 740c, 741c
Monocyte - adhesion - glycated vessel-wall protein 329
- receptor - advanced glycation end-product 329
Morphometry - capillary - endoneural 611
Mortality - diabetes - causes 538
- - cerebrovascular disease 244
- - insulin-treated - onset age over 30y A196
- - international variations 477
- - myocardial infarction 244
- - prospective study 538, 542
- - risk factors 542
- - trends - England & Wales A197
- - triglyceride, serum, and A57
- - Type 1 - Finland A17
- - - Norway A17
- ratio - standardised 538
Mouse - C57BL/6J - streptozotocin diabetes - interleukin 2 receptor Ab 266
- C57Bl/Ks - *db/db* - nerve enzymes 131
- *db/db* [see Mouse - C57Bl]
- - genetic analysis A96
- - hepatic cholesterol synthesis A206
- embryo culture - glucose, effect of 593
- NC - Reovirus-induced diabetes 192
- NOD (Non-obese diabetic)
- - bone marrow transplantation studies 84
- - diabetes - environmental factors 709
- - - - temperature 635
- - - MHC restriction 84
- - diabetes-resistant hybrid - NODxCBA 84
- - glucose treatment, neonatal A61
- - immunotherapy - FK-506 503
- - - Ling Zhi-8 713
- - insulin response to different stimuli A95
- - insulitis A62
- - - marker A62
- - - T-cells - $CD4^+$ - Vß8 gene-product A62
- - - - cytotoxic - MHC-restricted A62
- - islet - proliferation of cells A189
- - NK cell role - anti-Asialo GM-1 antibody study A192
- - sialitis A174
- - T-cell transfer of diabetes - insulin, prevention by A61
- - tumour necrosis factor A193
- *ob/ob* - erythrocyte deformability 127
- - islet glucose cycling A105
- - pancreatic galanin reduced A27
- obese hyperglycaemic - goldthioglucose-induced - acarbose effect 24
- streptozotocin diabetes - traditional plant remedies in 462
Muscle - heart [see Heart]
Muscle - skeletal [see also Glucose - transport/transporter; Myocyte]
- - adenosine deaminase - insulin, effect of A221
- - calcium flux - denervation 72
- - - diabetes 72
- - fatty acid, effect of 396
- - glucose transporter expression - Type 2 diabetes 625
- - glucose utilisation - fasting A219
- - glycogen phosphorylase - glucose-insulin infusion A221
- - glycogenolysis - glucocorticoid, effect of A219
- - protein synthesis 43
Myocyte - L6 - glucose transporter gene regulation 641

N

NEFA [see Fatty acid]
Nephropathy - diabetic [see also Albumin excretion; Angiotensin; Antiport; Countertransport; Kidney; Microalbuminuria; Microangiopathy; Urine; Transplantation - pancreas]
- diabetic - ACE inhibitors 121r
- - - with other antihypertensive trtmt A75
- - advanced - ACE inhibitor treatment A145
- - - leucine metabolism A207
- - - prognosis A145, A146
- - - Type 2 diabetes A146
- - blood viscosity and 576c
- - cardiovascular risk - familial A66
- - - factors A48, A142
- - early - ANP and cAMP A153
- - exercise, preventative effect of - rat A149
- - familial A30
- - fibroblast - glycosaminoglycan synthesis A66
- - genetic predisposition? 619
- - genetics - Pima Indians 438
- - HMG-CoA reductase inhibitor, effect of A65
- - hypertension and 121r, 407, 619
- - IGF-I and IGF-binding protein A154
- - magnetic resonance imaging of kidneys A147
- - metabolic control and A142
- - - dog 522
- - Na^+/H^+ antiport activity 371
- - - protein kinase C 278
- - Na^+/Li^+ countertransport - not inherited 619
- - painful *vs* painless - neurophysiology A16
- - spermidine - erythrocyte A31
- - study group A1w
- - thromboxane synthase inhibition, effect of A76
- galactosaemic - aldose reductase inhibitor 515
- hyperinsulinaemic normoglycaemic MF-hGH transgenic mouse A148
Nerve - aldose reductase - diabetes - *db/db* mouse 131

- ATPase - diabetes - *db/db* mouse 131
- - Na^+/K^+ - insulin, effect of - protein kinase C A28
- conduction - *myo*-inositol, effect of - diabetic rat A92
Nesidioblastosis 482
Neural tube - *myo*-inositol 593
Neurone - marker - cutaneous - diabetes A15
Neuropathy - autonomic [see also Death - sudden]
- - acetyl choline release - diabetic rat A162
- - assessment - skin blood flow, distant cooling A24
- - cardiovascular - clinical tests 177r
- - - clinical tests 180r, 182r, 640c
- - diabetic - baro reflex sensitivity A160
- - - circadian blood pressure variation A33
- - - ECG - QT interval A163
- - - endoneural capillary morphometry 611
- - - exercise 148, 739c
- - - gallbladder motility A162
- - - heart rate - power spectral analysis A160
- - - immunology A33
- - - muscle sympathetic nerve response A165
- - - nephropathy, association with? A164
- - - noradrenaline, plasma A164
- - - pancreas/kidney transplant, after A34
- - - pancreatic polypeptide in A161, A162
- - - postural hypotension - xamoterol A92
- - - silent myocardial ischaemia A171
- - - skin blood-flow response to pressure A164
- - - skin sympathetic response A159
- - - sweat spot count A159
- - - urinary bladder A161
- - - visceral afferent A34
- - gastric emptying - hyperglycaemia effect 675
- - sympathetic - diabetes 350
- - - peripheral vasoconstriction 350
- - - postural hypotension 350
- - testing - venous occlusion plethysmography 350
- central - diabetes, early A16
- diabetic - aldose reductase inhibitor trial 431, A91, A92, A167
- - α-adrenoceptor blockade, prevention by - rat A92
- - assessment - non-invasive tests *vs* morphology A15
- - - reproducibility A15
- - bone mineral density A168
- - duration of diabetes and A166
- - endoneural capillary morphometry 611
- - essential fatty acid, dietary - rat A165, A166
- - hypoxia, possible role 311
- - metabolic control and A166
- - microangiopathy, possible role 311
- - painful - mexiletine treatment A91
- - prevalence - childhood diabetes A33, A165
- - tests - blood glucose, effect of A166
- - - vibration and thermal threshold A167
- hereditary - endoneural capillary morphometry 611
- hypoxic - relevance to diabetic neuropathy? 311
Neurophysiology - EEG - hypoglycaemia 319
- evoked response - auditory P300 319
- - diabetes A167
- - somatosensory 319
- - - early diabetes A15
Nicotinamide [see also Interleukin]
- Type 1 diabetes, use in 444
Nitrogen - wastage in diabetes - glucagon role A222
NOD mouse [see Mouse - NOD]
Nurse - diabetes specialist - cost saving A131
Nutrition - diabetes - study group A2w

O

Obesity [see also Fat; Rat - *fa/fa*]
- adipocyte insulin binding A229
- β-endorphin, insulin response to A213
- experimental hypothalamic - insulin release A214
- glucose metabolism 228
- hyperinsulinaemia - mechanism A214
- insulin handling A216
- lipid metabolism 228
- treatment - dexfenfluramine - diabetes A124
- - fluoxetine - diabetes A124
- Type 2 diabetes - glucose disposal A213
- - impaired thermogenesis role A213
Oncogene - expression - ßTC1 insulinoma cell 586
Oxygen - uptake - glucose tolerance testing and 526
Oxyntomodulin - receptor - RIN T3 cell A98

P

Pancreas - artificial [see also Clamp]
- bioartificial [see Transplantation - islet]
- biopsy - laparoscopic 105
- exocrine - cytokeratin - antibody in Type 1 diabetes 363
- - function - tropical calcific pancreatitis 417
- - Type 1 diabetes - cytokeratin antibodies 363
- isolated, perfused - pancreastatin effects 403
- perfused - rat - interleukin 1ß, effects of 15
- size - ultrasonography - Type 1 diabetes A135
Pancreastatin - pancreas, effect on - pig 403
- secretion - pig A98
Pancreatitis - tropical - calcific - islet function 417
- tropical - calcific - pancreatic exocrine function 417
Peptide - amyloid - islet [see Amylin]
pH - intracellular - leucocyte 278
pH - intracellular - leucocyte 371
Phagocyte [see Macrophage; Leucocyte - neutrophil; Langerhans cell]
- function - diabetes - neutrophil *vs* macrophage A50
Pig - pancreas - isolated, perfused - pancreastatin effects 403
Pima Indian - amylin gene sequence 628
- diabetic nephropathy genetics 438
- Type 2 diabetes - islet amyloid and 285
Plasminogen [see also Fibrinolysis]
- activator inhibitor - Type 2 diabetes - split proinsulin 532
Platelet - exercise, during - albuminuria and - diabetes A159
- glycoprotein - diabetes - megakaryocyte ploidity and A159
- immune neutralisation - diabetes A157
- volume - diabetes A158
Poly(ADP-ribose) synthetase inhibitor - islet regeneration 250
Polymerase chain reaction - amylin gene 628
- HLA-DQB 174
Prediabetes - NOD mouse 709
- Type 1 - immunotherapy - randomised trials needed 741c
- - impaired glucose tolerance - twin study 497
- Type 2 - insulin resistance A209
Prediction [see Diabetes - Type 1; -Type 2]
Pregnancy [see also Embryo; Fetus; Diabetes - gestational]
- blastocyst development - diabetic rat 187
- diabetes - erythropietin, fetal 378
- - fetal malformations - HbA1 and A138
- - fructosamine assay A139
- - management - UK survey A139
- - outcome - Norway A137
- - premature labour - nifedipine in A55
- - study group A1w
- diabetes diagnosed in - Type 1 31
- early - diabetes - outcome and HbA1 100
- obesity - fetal weight and A138
- placental hormones - diabetes A139
Proinsulin - C-peptide ratio - Type 1 diabetes immunotherapy, in 36
- cleavage - permeabilised rat islet A37
- plasma - obesity and Type 2 diabetes A212
- - Type 2 diabetes - cardiovascular risk factors and 532
- production - transfected hepatoma cells - dexamethasone A93
- secretion - hyperglycaemic clamp study A86
- serum - Type 1 diabetes - family study A68
- split - Type 2 diabetes - cardiovasc'r risk factors 532
- therapy - coronary heart disease increased? A60
Prostacyclin [see Foot - ischaemia]
Prostaglandin - neural tube fusion, role in 593

Protein - synthesis - insulin, effect of - man 43
- turnover - Type 1 diabetes 43
Proteolysis - estimation - primary pool model of leucine A223
- insulin, reduction by - extramuscular A223
Psychology - Type 1 diabetes A129
Puberty - female - diabetes, effect of A140
Pulsatility [see also B-cell, pancreatic - calcium; Islet - calcium; Insulin]
- glucagon secretion 272
Pupillary light reflex - hyperglycaemia, effect of A156
Pyruvate - dehydrogenase - fatty acid, effect of 396

Q

Quality of life - diabetes A129, A130

R

Radical, free - diabetes A135
- - metabolic control and A176
Rat - BB - diabetes - theophylline, protection by 506
- - diabetes prevention by drugs A189
- - diabetic - HbA1 257
- - diet A189
- - ganglioside, pancreatic - autoimmunity and A192
- - islet regeneration - gene A82
- - tumour necrosis factor 573, A193
- embryo culture - glucose, effect of 597
- *fa/fa* - juvenile pre-obese - glucose transporter expression A32
- - lipid storage enzyme expression increased A29
- - retinopathy 137
- galactosaemic - glomerular basement membrane thickening 515
- GK - insulin resistance A229
- glucose turnover - fatty acid, effect of 396
- intestine - ileal epithelium - insulin absorption 197
- pancreatectomy - partial - islet regeneration 250
- pancreatic B cell perifusion 649
- streptozotocin diabetes - islet transplantation 112
- - islet xenograft - function 457
- - renal basement membrane collagen 661
- - pregnancy - blastocyst 187
- - renal hypertrophy 334
Reaven hypothesis [see Insulin - resistance - cardiovascular risk factors]
Renal [see also Kidney]
Renal failure - chronic - metabolic changes A222
Renin-angiotensin-aldosterone system: Type 1 diabetes & exercise 148, 637, 739 c
Reovirus 192
Restriction fragment length polymorphism [see Genetics]
Retina - blood flow [see also Endothelin]
- - hypoglycaemia, effect of 262
- cell growth - glucose, effect of A70
- electroretinogram - pattern - Type 1 diabetes - early 726
- *fa/fa* rat 137
- function - Type 1 diabetes A89
- microvascular mRNA measurement A70
Retinopathy, diabetic - albumin excretion rate and A156
- aldose reductase inhibitor effect A89
- early changes - electroretinogram 726
- *fa/fa* rat model 137
- hepatic cirrhosis, protection by - IGF-I A155
- hypertension and 407, A69
- IGF-I in A89
- laminin, serum A156
- metabolic control and A69, A89
RFLP (restriction fragment length polymorphism) [See Genetics]
Risk - factors - Type 2 diabetes 3r
RNA - messenger - IGF-I (Somatomedin-C) - antibody, monoclonal 191

S

Screening - diabetes - impaired glucose tolerance and 526
- glycosuria - postal A131
Seychelles, Republic of - insulin-treated diabetes 184c
Sodium - excretion [see also Renin; Atrial natriuretic; Hypertension]
- retention - diabetes - ANP, role of A21
- - insulin-induced A21
- - - Type 2 diabetes A21
- transport [see also Antiport]
Somatomedin - inhibitor - Type 1 diabetes A217
Somatostatin - adipocyte, effect on - insulin sensitivity A228
- analogue - renal effects of diabetes, effect on A65
- - Type 1 diabetes, use in A218
- receptor - islet B-cell - hamster A98
- secretion - pancreastatin, effect of 403
Sorbitol - rat embryo culture 597
Splenocyte - streptozotocin diabetes 9
Steele's equations 603
Stomach - emptying - hyperglycaemia, effect of 675
Streptozotocin - B-cell, pancreatic, effect on 654
- diabetes - B-cell-adherent splenocytes preceding 9
- - interleukin 2 receptor antibody, effect of 266
- - islet mitochondrial function A94
- - rat - pregnancy 187
- - reversible - pancreatic cell morphometry A108
- - traditional plant remedies, effect of 462
- - vanadate, effect of 62c
- low-dose - cell-mediated immunity induction A195
- NOD mouse, effect on 709
Stroke - prognosis - diabetes 244
Sulphonylurea - biguanide, combined with - metabolic effects A125
- cardiovascular effects A53
- glibenclamide 145
- gliclazide - free-radical scavenging A125
- - insulin secretion, effect on A53
- insulin release, effect on - islet B-cell adrenoceptors 145
- islet B-cell, effect on - Na^+ entry A78
- islet-cell, effect on - Ca^{2+}, free A103
- receptor A79
- - ligand, endogenous - rat CNS A79
- - Mg^{2+}-ATP and A78
- thalassaemia major, non-diabetic, use in A125
- tolbutamide 145
- - myocardial effect - ischaemia A53
- treatment - insulin, combined with 688
Surgery - diabetes - Type 2 A114
Syndrome X [see Insulin - resistance - cardiovascular risk factors]

T

Temperature - diabetes incidence and - NOD mouse 635
- NOD mouse, effect on 635
Thalassaemia [see also Sulphonylurea]
Thalassaemia major - insulin resistance A216
Thromboembolism [see Blood - coagulation]
Thrombolytic therapy - fibrinogen glycation, effect of A46
Thromboxane - synthase - inhibitor - FCE-22178 A76
Thyrotropin-releasing hormone - islet A109
Tolbutamide [see Sulphonylurea]
Transferrin - urinary - exercise, effect of - diabetes A155
Transplantation [see also Cyclosporin]
- islet [see also Islet - microencapsulation]
- - BB rat - genetic factors A179
- - diffusion chamber A43
- - ganglioside pretreatment 112
- - glucose toxicity? A180
- - human A38
- - immunosuppression - 15-deoxyspergualin A179
- - - anti-IL-2-receptor Ab A180
- - insulin clearance following A180
- - interleukin-1ß toxicity, protection from A194
- - intrasplenic venous - dog A178
- - intrathecal - rat A179
- - microencapsulated - animal model A42
- - - intravascular prosthesis A42
- - - *vs* free - peritoneal A42
- - portal *vs* peripheral site - rat A179
- - reinnervation A43
- - rejection - $CD4^+/CD8^+$ ratio A180
- - renal subcapsular - rat A178
- - xenograft - insulin assay by HPLC 457
- - - microencapsulation 457
- - - porcine in rat 457
- kidney - diabetes - outcome A146
- - insulin resistance and 549
- pancreas [see also Neuropathy - autonomic]
- - diabetic nephropathy, effect on A37
- - incretin effect A38

- - insulin resistance after A38
- - kidney, combined - insulin resistance and 549
- - - quality of life A37
Triglyceride - serum - coronary disease risk factor 489
Tropical fibrocalculous diabetes [see Diabetes - pancreatic - fibrocalculous]
Tumour necrosis factor - α - diabetic BB rat 573

U

Urinary tract infection - *E. coli* adherence and - diabetic women A146
Urine - NAG (N-acetyl-ß-D-glucosidase) - Type 2 diabetes A153

V

Vanadate - adipocyte, effect on - human A229
- diabetic rat adipocyte, effect on A70
- insulin sensitivity, effect on - rat A71
- peroxo- - diabetic rat muscle, effect on A70
- streptozotocin diabetes, effect in - vanadium toxicity 62c
Virus - antibodies - Type 1 diabetes - Finland A67
- CMV - RNA sequence in pancreas - Type 2 diabetes A190
- Coxsackie B - antibodies - Type 1 diabetes - Czechoslovakia A67
- - capsid antigen - islet - myocarditis; diabetes 290
- - islet, effect on - preproinsulin mRNA A191
- - human isolates - mouse islets, effect on in vitro 325
- cytomegalovirus - islet-cell antigen 38kD and 569
- - monoclonal antibody 569
- ECHO - 4 - islet, effect on - mouse A190
- entero - Type 1 diabetes - epidemiology - Poland A198
- mumps - islet B cell, effect on - human fetal A190
- Reovirus Type 2 - diabetogenic in mice 192
- retro- - DNA sequence - polyendocrinopathy A190
Visual function - diabetes - microalbuminuria and A155
Vitamin - D - 1,25$(OH)_2$ - diabetes - metabolic control and A174

W

WHO (World Health Organisation)
- Multinational Study of Vascular Disease in Diabetic Patients 477, 538, 542